15 Jun Froedtert & MCW PREVENTABLE study now recruiting participants for dementia, cardiovascular disease study
The Froedtert & the Medical College of Wisconsin health network is the second leading recruiting site in the country for PREVENTABLE, an NIH funded randomized trial trying to determine whether healthy people 75 years of age or older without cardiovascular disease are less likely to develop dementia, disability or cardiovascular disease if they are treated with atorvastatin, a drug commonly used to lower cholesterol. More than 20,000 participants across 100 sites in the US will make up one of the largest studies ever conducted in older adults.
The study will randomize participants without heart disease or dementia to receive either atorvastatin or placebo. Researchers will follow participants for up to five years, test their memory, thinking, and physical abilities, and monitor them for events such as heart attacks or strokes.
The MCW site is currently top three in the nation for enrollment and is led by Dr. Jeffrey Whittle, MD and Dr. Jake Decker, MD. CTSI team members consist of Kris Osinski, MS from Biomedical Informatics alongside Madeline Berendt, BS and Kelsey Rice, BS from the Clinical Trials Office.